Safety evaluation after acute and sub-chronic oral administration of high purity Nicotinamide mononucleotide (NMN-C®) in Sprague-Dawley rats.

doi:10.1016/j.fct.2021.112060

Paper

Safety evaluation after acute and sub-chronic oral administration of high purity Nicotinamide mononucleotide (NMN-C®) in Sprague-Dawley rats.

Published Feb 12, 2021 · Cécile D. Cros, Hélène Cannelle, L. Laganier

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association

Q1 SJR score

13

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

NMN-C® is safe for short to intermediate term oral administration in rats, with a No-Observable Adverse Effect Level (NOAEL) of ≥ 1500 mg/kg/d.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Safety evaluation after acute and sub-chronic oral administration of high purity Nicotinamide mononucleotide (NMN-C®) in Sprague-Dawley rats.

References

Citations